Lung cancer nanomedicine: Potentials and pitfalls

Nanomedicine

Volumn 10, Issue 21, 2015, Pages 3203-3212

  Bolukbas, Deniz Ali ^a   Meiners, Silke ^a  

^a UNIVERSITY OF MUNICH   (Germany)

Author keywords

Active targeting; clinical studies; lung cancer therapy; nanomedicine; nanoparticle; tumor mouse model

Indexed keywords

ANTINEOPLASTIC AGENT; NANOMATERIAL; NANOPARTICLE;

ARTICLE; CANCER THERAPY; CLINICAL STUDY; CLINICAL TRIAL (TOPIC); DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG RELEASE; DRUG SCREENING; FOOD AND DRUG ADMINISTRATION; HUMAN; LUNG CANCER; MOLECULARLY TARGETED THERAPY; NANOMEDICINE; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; ANIMAL; LUNG NEOPLASMS;

ANIMALS; HUMANS; LUNG NEOPLASMS; NANOMEDICINE;

EID: 84944343138     PISSN: 17435889     EISSN: 17486963     Source Type: Journal    
DOI: 10.2217/nnm.15.155     Document Type: Article

References (118)

1. Ferlay J, Soerjomataram I, Ervik M et al. GLOBOCAN 2012 v1. 0. Cancer incidence and mortality worldwide: IARC CancerBase. http://globocan.iarc.fr/Default.aspx
2. Network CGaR. Comprehensive molecular profiling of lung adenocarcinoma. Nature 511(7511), 543-550 (2014).
3. Jett JR, Carr LL. Targeted therapy for non-small cell lung cancer. Am. J. Respir. Crit. Care Med. 188(8), 907-912 (2013).
4. Chen Z, Fillmore CM, Hammerman PS, Kim CF, Wong K-K. Non-small-cell lung cancers: a heterogeneous set of diseases. Nat. Rev. Cancer 14(8), 535-546 (2014).
5. Kauczor H-U, Bonomo L, Gaga M et al. ESR/ERS white paper on lung cancer screening. Eur. Respir. J. ERJ-00330-02015 (2015).
6. Collins LG, Haines C, Perkel R, Enck RE. Lung cancer: diagnosis and management. Am. Fam. Physician 75(1) 56-63 (2007).
7. Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R Langer R. Nanocarriers as an emerging platform for cancer therapy. Nat. Nanotechnol. 2(12), 751-760 (2007).
8. Duncan R, Gaspar R. Nanomedicine (s) under the microscope. Mol. Pharm. 8(6), 2101-2141 (2011).
9. Schütz CA, Juillerat-Jeanneret L, Mueller H, Lynch I Riediker M. Therapeutic nanoparticles in clinics and under clinical evaluation. Nanomedicine 8(3), 449-467 (2013).
10. Wagner V, Dullaart A, Bock A-K, Zweck A. The emerging nanomedicine landscape. Nat. Biotechnol. 24(10), 1211-1217 (2006).
11. Wang AZ, Langer R, Farokhzad OC. Nanoparticle delivery of cancer drugs. Annu. Rev. Med. 63 185-198 (2012).
12. Doane TL, Burda C. The unique role of nanoparticles in nanomedicine: imaging, drug delivery and therapy. Chem. Soc. Rev. 41(7), 2885-2911 (2012).
13. Sung JC, Pulliam BL, Edwards DA. Nanoparticles for drug delivery to the lungs. Trends Biotechnol. 25(12), 563-570 (2007).
14. Van Rijt SH, Bein T, Meiners S. Medical nanoparticles for next generation drug delivery to the lungs. Eur. Respir. J. 44(3), 765-774 (2014).
15. Choi HS, Ashitate Y, Lee JH et al. Rapid translocation of nanoparticles from the lung airspaces to the body. Nat. Biotech. 28(12), 1300-1303 (2010).
16. Lu X, Zhu T, Chen C, Liu Y. Right or left: the role of nanoparticles in pulmonary diseases. Int. J. Mol. Sci. 15(10) 17577-17600 (2014).
17. Ruge CA, Kirch J, Lehr C-M. Pulmonary drug delivery: from generating aerosols to overcoming biological barrierstherapeutic possibilities and technological challenges. Lancet Respir. Med. 1(5), 402-413 (2013).
18. Thorley AJ, Tetley TD. New perspectives in nanomedicine. Pharmacol. Ther. 140(2), 176-185 (2013).
19. Ozeki T, Tagami T. Drug/polymer nanoparticles prepared using unique spray nozzles and recent progress of inhaled formulation. Asian J. Pharm. Sci. 9(5), 236-243 (2014).
20. Howell M, Wang C, Mahmoud A, Hellermann G Mohapatra S, Mohapatra S. Dual-function theranostic nanoparticles for drug delivery and medical imaging contrast: perspectives and challenges for use in lung diseases. Drug Deliv. Transl. Res. 3(4), 352-363 (2013).
21. Babu A, Templeton AK, Munshi A, Ramesh R. Nanoparticle-based drug delivery for therapy of lung cancer: progress and challenges. J. Nanomater. 2013, 14 (2013).
22. Sukumar UK, Bhushan B, Dubey P, Matai I, Sachdev A Packirisamy G. Emerging applications of nanoparticles for lung cancer diagnosis and therapy. Int. Nano Lett. 3(1), 1-17 (2013).
23. Key J, Kim Y-S, Tatulli F et al. Opportunities for nanotheranosis in lung cancer and pulmonary metastasis. Clin. Transl. Imaging 2(5), 427-437 (2014).
24. Chandolu V, R Dass C. Treatment of lung cancer using nanoparticle drug delivery systems. Curr. Drug Discov. Technol. 10(2), 170-176 (2013).
25. Badrzadeh F, Rahmati-Yamchi M, Badrzadeh K et al. Drug delivery and nanodetection in lung cancer. Artif. Cells Nanomed. Biotechnol. 1-17 (2014) (Epub ahead of print).
26. Bandyopadhyay A, Das T, Yeasmin S. Nanoparticles in Lung Cancer Therapy: Recent Trends. Springer, NNY, USA (2015).
27. Kim Y-D, Park T-E, Singh B et al. Nanoparticle-mediated delivery of siRNA for effective lung cancer therapy. Nanomedicine 10(7), 1165-1188 (2015).
28. Fujita Y, Kuwano K, Ochiya T. Development of small RNA delivery systems for lung cancer therapy. Int. J. Mol. Sci. 16(3), 5254-5270 (2015).
29. Matsumura Y, Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res. 46(12 Part 1), 6387-6392 (1986).
30. Gu FX, Karnik R, Wang AZ et al. Targeted nanoparticles for cancer therapy. Nano Today 2(3), 14-21 (2007).
31. Crisp JL, Savariar EN, Glasgow HL, Ellies LG, Whitney MA, Tsien RY. Dual targeting of integrin v3 and matrix metalloproteinase-2 for optical imaging of tumors and chemotherapeutic delivery. Mol. Cancer Ther. 13(6) 1514-1525 (2014).
32. Van Rijt SH, Bölükbas DA, Argyo C et al. Protease-mediated release of chemotherapeutics from mesoporous silica nanoparticles to ex vivo human and mouse lung tumors. ACS Nano 9(3), 2377-2389 (2015).
33. Sadhukha T, Wiedmann TS, Panyam J. Inhalable magnetic nanoparticles for targeted hyperthermia in lung cancer therapy. Biomaterials 34(21), 5163-5171 (2013).
34. Kim I, Byeon HJ, Kim TH et al. Doxorubicin-loaded porous PLGA microparticles with surface attached TRAIL for the inhalation treatment of metastatic lung cancer. Biomaterials 34(27), 6444-6453 (2013).
35. Choi SH, Byeon HJ, Choi JS et al. Inhalable self-assembled albumin nanoparticles for treating drug-resistant lung cancer. J. Control. Release 197 199-207 (2015).
36. Conde J, Tian F, Hernández Y et al. In vivo tumor targeting via nanoparticle-mediated therapeutic siRNA coupled to inflammatory response in lung cancer mouse models. Biomaterials 34(31), 7744-7753 (2013).
37. Taratula O, Kuzmov A, Shah M, Garbuzenko OB, Minko T. Nanostructured lipid carriers as multifunctional nanomedicine platform for pulmonary co-delivery of anticancer drugs and siRNA. J. Control. Release 171(3) 349-357 (2013).
38. Taratula O, Garbuzenko OB, Chen AM, Minko T. Innovative strategy for treatment of lung cancer: targeted nanotechnology-based inhalation co-delivery of anticancer drugs and siRNA. J. Drug Targeting 19(10), 900-914 (2011).
39. Lammers T, Kiessling F, Hennink WE, Storm G. Drug targeting to tumors: principles, pitfalls and (pre-) clinical progress. J. Control. Release 161(2), 175-187 (2012).
40. Malaney P, Nicosia SV, Davé V. One mouse, one patient paradigm: new avatars of personalized cancer therapy. Cancer Lett. 344(1), 1-12 (2014).
41. Khaled WT, Liu P. Cancer mouse models: past, present and future. Semin. Cell Dev. Biol. doi: 10.1016/j. semcdb.2014.04.003 (2014) (Epub ahead of print).
42. Hrkach J, Von Hoff D, Ali MM et al. Preclinical development and clinical translation of a PSMA-Targeted docetaxel nanoparticle with a differentiated pharmacological profile. Sci. Transl. Med. 4(128), 128-139 (2012).
43. Talelli M, Barz M, Rijcken CJ, Kiessling F, Hennink WE Lammers T. Core-crosslinked polymeric micelles: principles preparation, biomedical applications and clinical translation. Nano Today 10(1), 93-117 (2015).
44. Grilley-Olson JE, Keedy VL, Sandler A, Moore DT, Socinski MA, Stinchcombe TE. A randomized Phase II study of carboplatin with weekly or every-3-week nanoparticle albumin-bound paclitaxel (abraxane) in patients with extensive-stage small cell lung cancer. Oncologist 20(2) 105-106 (2015).
45. Lammers PE, Lu B, Horn L, Shyr Y, Keedy V. nab-Paclitaxel in combination with weekly carboplatin with concurrent radiotherapy in stage iii non-small cell lung cancer. Oncologist 20(5), 491-492 (2015).
46. Langer CJ, Hirsh V, Ko A, Renschler MF, Socinski MA. Weekly nab-paclitaxel in combination with carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: analysis of safety and efficacy in patients with renal impairment. Clin. Lung Cancer 16(2), 112-120 (2014).
47. Barenholz YC. Doxil®-The first FDA-approved nano-drug: lessons learned. J. Control. Release 160(2), 117-134 (2012).
48. Koukourakis M, Koukouraki S, Giatromanolaki A et al. Liposomal doxorubicin and conventionally fractionated radiotherapy in the treatment of locally advanced nonsmall-cell lung cancer and head and neck cancer. J. Clin. Oncol. 17(11), 3512-3521 (1999).
49. Koukourakis M, Romanidis K, Froudarakis M et al. Concurrent administration of Docetaxel and Stealth® liposomal doxorubicin with radiotherapy in non-small cell lung cancer: excellent tolerance using subcutaneous amifostine for cytoprotection. Br. J. Cancer 87(4), 385-392 (2002).
50. Patlakas G, Bouros D, Tsantekidou-Pozova S, Koukourakis MI. Triplet chemotherapy with docetaxel, gemcitabine and liposomal doxorubicin, supported with subcutaneous amifostine and hemopoietic growth factors, in advanced nonsmall cell lung cancer. Anticancer Res. 25(2B), 1427-1431 (2005).
51. Tsoutsou PG, Froudarakis ME, Bouros D, Koukourakis MI. Hypofractionated/accelerated radiotherapy with cytoprotection (HypoARC) combined with vinorelbine and liposomal doxorubicin for locally advanced non-small cell lung cancer (NSCLC). Anticancer Res. 28(2B), 1349-1354 (2008).
52. Numico G, Castiglione F, Granetto C et al. Single-agent pegylated liposomal doxorubicin (Caelix® ) in chemotherapy pretreated non-small cell lung cancer patients: a pilot trial. Lung Cancer 35(1), 59-64 (2002).
53. Samantas E, Kalofonos H, Linardou H et al. Phase II study of pegylated liposomal doxorubicin: inactive in recurrent small-cell lung cancer a Hellenic Cooperative Oncology Group Study. Ann. Oncol. 11(11), 1395-1397 (2000).
54. Skubitz KM. Phase II trial of PEGylated-liposomal Doxorubicin (Doxil™) in mesothelioma 1. Cancer Invest. 20(5-6), 693-699 (2002).
55. Fantini M, Gianni L, Santelmo C et al. Lipoplatin treatment in lung and breast cancer. Chemother. Res. Pract. 2011, 125192 (2010).
56. Stathopoulos G, Antoniou D, Dimitroulis J, Stathopoulos J, Marosis K, Michalopoulou P. Comparison of liposomal cisplatin versus cisplatin in non-squamous cell non-small-cell lung cancer. Cancer Chemother. Pharmacol. 68(4), 945-950 (2011).
57. Stathopoulos G, Boulikas T. Lipoplatin formulation review article. J. Drug Deliv. 2012 581363 (2011).
58. NIH Clinical Trials Register. https://clinicaltrials.gov/
59. Samyang Biopharmaceuticals. www.samyangbiopharm.com/eng
60. Kim D-W, Kim S-Y, Kim H-K et al. Multicenter Phase II trial of Genexol-PM, a novel cremophor-free, polymeric micelle formulation of paclitaxel, with cisplatin in patients with advanced non-small-cell lung cancer. Ann. Oncol. 18(12), 2009-2014 (2007).
61. Kim HJ, Kim KH, Yun J et al. Phase II clinical trial of Genexol® (Paclitaxel) and carboplatin for patients with advanced non-small cell lung cancer. Cancer Res. Treat. 43(1), 19-23 (2011).
62. Ahn HK, Jung M, Sym SJ et al. A Phase II trial of cremorphor EL-free paclitaxel (Genexol-PM) and gemcitabine in patients with advanced non-small cell lung cancer. Cancer Chemother. Pharmacol. 74(2), 277-282 (2014).
63. Peng X-H, Wang Y, Huang D et al. Targeted delivery of cisplatin to lung cancer using ScFvEGFR-heparin-cisplatin nanoparticles. ACS Nano 5(12), 9480-9493 (2011).
64. Cheng L, Huang F-Z, Cheng L-F et al. GE11-modified liposomes for non-small cell lung cancer targeting: preparation, ex vitro and in vivo evaluation. Int. J. Nanomedicine 9, 921 (2014).
65. Sundarraj S, Thangam R, Sujitha MV, Vimala K, Kannan S. Ligand-conjugated mesoporous silica nanorattles based on enzyme targeted prodrug delivery system for effective lung cancer therapy. Toxicol. Appl. Pharmacol. 275(3), 232-243 (2014).
66. Karra N, Nassar T, Ripin AN, Schwob O, Borlak J, Benita S. Antibody conjugated PLGA nanoparticles for targeted delivery of paclitaxel palmitate: efficacy and biofate in a lung cancer mouse model. Small 9(24), 4221-4236 (2013).
67. Yonenaga N, Kenjo E, Asai T et al. RGD-based active targeting of novel polycation liposomes bearing siRNA for cancer treatment. J. Control. Release 160(2), 177-181 (2012).
68. Liu L, Liu X, Xu Q et al. Self-assembled nanoparticles based on the c (RGDfk) peptide for the delivery of siRNA targeting the VEGFR2 gene for tumor therapy. Int. J. Nanomedicine 9 3509 (2014).
69. Li J, Chen Y-C, Tseng Y-C, Mozumdar S, Huang L. Biodegradable calcium phosphate nanoparticle with lipid coating for systemic siRNA delivery. J. Control. Release 142(3), 416-421 (2010).
70. Li J, Yang Y, Huang L. Calcium phosphate nanoparticles with an asymmetric lipid bilayer coating for siRNA delivery to the tumor. J. Control. Release 158(1), 108-114 (2012).
71. Zhang Y, Kim WY, Huang L. Systemic delivery of gemcitabine triphosphate via LCP nanoparticles for NSCLC and pancreatic cancer therapy. Biomaterials 34(13) 3447-3458 (2013).
72. Yang Y, Hu Y, Wang Y, Li J, Liu F, Huang L. Nanoparticle delivery of pooled siRNA for effective treatment of non-small cell lung caner. Mol. Pharm. 9(8), 2280-2289 (2012).
73. Yang Y, Li J, Liu F, Huang L. Systemic delivery of siRNA via LCP nanoparticle efficiently inhibits lung metastasis. Mol. Ther. 20(3), 609-615 (2012).
74. Zhang Y, Schwerbrock NM, Rogers AB, Kim WY Huang L. Codelivery of VEGF siRNA and gemcitabine monophosphate in a single nanoparticle formulation for effective treatment of NSCLC. Mol. Ther. 21(8), 1559-1569 (2013).
75. Ganesh S, Iyer AK, Weiler J, Morrissey DV, Amiji MM. Combination of siRNA-directed gene silencing with cisplatin reverses drug resistance in human non-small cell lung cancer. Mol. Ther. Nucl. Acids 2(7), e110 (2013).
76. Ganesh S, Iyer AK, Morrissey DV, Amiji MM. Hyaluronic acid based self-assembling nanosystems for CD44 target mediated siRNA delivery to solid tumors. Biomaterials 34(13), 3489-3502 (2013).
77. Guo L, Fan L, Ren J et al. Combination of TRAIL and actinomycin D liposomes enhances antitumor effect in nonsmall cell lung cancer. Int. J. Nanomedicine 7 1449 (2012).
78. Taratula O, Garbuzenko O, Savla R, Andrew Wang Y, He H Minko T. Multifunctional nanomedicine platform for cancer specific delivery of siRNA by superparamagnetic iron oxide nanoparticles-dendrimer complexes. Curr. Drug Deliv. 8(1) 59-69 (2011).
79. Gray BP, Mcguire MJ, Brown KC. A liposomal drug platform overrides peptide ligand targeting to a cancer biomarker, irrespective of ligand affinity or density. PLoS ONE 8(8), e72938 (2013).
80. Shen J, Meng Q, Sui H et al. iRGD Conjugated TPGS mediates codelivery of paclitaxel and survivin shRNA for the reversal of lung cancer resistance. Mol. Pharm. 11(8) 2579-2591 (2013).
81. Mitchell MJ, Wayne E, Rana K, Schaffer CB, King MR. TRAIL-coated leukocytes that kill cancer cells in the circulation. Proc. Natl Acad. Sci. USA 111(3), 930-935 (2014).
82. Guo Y, Wang L, Lv P, Zhang P. Transferrin-conjugated doxorubicin-loaded lipid-coated nanoparticles for the targeting and therapy of lung cancer. Oncol. Lett. 9(3) 1065-1072 (2015).
83. Han Y, Li Y, Zhang P et al. Nanostructured lipid carriers as novel drug delivery system for lung cancer gene therapy. Pharm. Dev. Technol. 1-5 (2015) (Epub ahead of print).
84. Patel AR, Chougule M, Singh M. EphA2 targeting pegylated nanocarrier drug delivery system for treatment of lung cancer. Pharm. Res. 31(10), 2796-2809 (2014).
85. Alberti D, Protti N, Toppino A et al. A theranostic approach based on the use of a dual boron/Gd agent to improve the efficacy of boron neutron capture therapy in the lung cancer treatment. Nanomed. Nanotechnol. Biol. Med. 11(3), 741-750 (2015).
86. Morton SW, Lee MJ, Deng ZJ et al. A nanoparticle-based combination chemotherapy delivery system for enhanced tumor killing by dynamic rewiring of signaling pathways. Sci. Signal. 7(325), ra44 (2014).
87. Sarfati G, Dvir T, Elkabets M, Apte RN, Cohen S. Targeting of polymeric nanoparticles to lung metastases by surface-attachment of YIGSR peptide from laminin. Biomaterials 32(1), 152-161 (2011).
88. Zhao S, Chu Z, Blanco VM, Nie Y, Hou Y, Qi X. SapC-DOPS nanovesicles as targeted therapy for lung cancer. Mol. Cancer Ther. 14(2), 491-498 (2015).
89. Shi H, Ye X, He X et al. Au@ Ag/Au nanoparticles assembled with activatable aptamer probes as smart "nano-doctors" for image-guided cancer thermotherapy. Nanoscale 6(15) 8754-8761 (2014).
90. Wang C, Ding C, Kong M et al. Tumor-Targeting magnetic lipoplex delivery of short hairpin RNA suppresses IGF-1R overexpression of lung adenocarcinoma A549 cells in vitro and in vivo. Biochem. Biophys. Res. Commun. 410(3) 537-542 (2011).
91. Chen Y, Zhu X, Zhang X, Liu B, Huang L. Nanoparticles modified with tumor-Targeting scFv deliver siRNA and miRNA for cancer therapy. Mol. Ther. 18(9), 1650-1656 (2010).
92. Wang Y, Xu Z, Guo S et al. Intravenous delivery of siRNA targeting CD47 effectively inhibits melanoma tumor growth and lung metastasis. Mol. Ther. 21(10), 1919-1929 (2013).
93. Liu J, Chu L, Wang Y et al. Novel peptide-dendrimer conjugates as drug carriers for targeting nonsmall cell lung cancer. Int. J. Nanomedicine 6 59-69 (2011).
94. Patel AR, Chougule MB, Lim E, Francis KP, Safe S, Singh M. Theranostic tumor homing nanocarriers for the treatment of lung cancer. Nanomed. Nanotechnol. Biol. Med. 10(5) 1053-1063 (2014).
95. Yang S-G, Chang J-E, Shin B, Park S, Na K, Shim C-K. 99mTc-hematoporphyrin linked albumin nanoparticles for lung cancer targeted photodynamic therapy and imaging. J. Mater. Chem. 20(41), 9042-9046 (2010).
96. Card JW, Zeldin DC, Bonner JC, Nestmann ER. Pulmonary applications and toxicity of engineered nanoparticles. Am. J. Physiol. Lung Cell. Mol. Physiol. 295(3), L400-L411 (2008).
97. Schulze K, Imbeaud S, Letouzé E et al. Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets. Nat. Genet. 47(5), 505-511 (2015).
98. Suzuki H, Aoki K, Chiba K et al. Mutational landscape and clonal architecture in grade II and III gliomas. Nat. Genet. 47(5), 505-511 (2015).
99. Rizvi NA, Hellmann MD, Snyder A et al. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 348(6230), 124-128 (2015).
100. Network CGaR. Comprehensive genomic characterization of squamous cell lung cancers. Nature 489(7417), 519-525 (2012).
101. Van De Wetering M, Francies HE, Francis JM et al. Prospective derivation of a living organoid biobank of colorectal cancer patients. Cell 161(4), 933-945 (2015).
102. Venditto VJ, Szoka FC. Cancer nanomedicines: so many papers and so few drugs! Adv. Drug Deliv. Rev. 65(1), 80-88 (2013).
103. Ozin G. Nanochemistry reproducibility. www.materialsviews.com/nanochemistry-reproducibility/
104. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 144(5), 646-674 (2011).
105. Twyman-Saint Victor C, Rech AJ, Maity A et al. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature 520(7547), 373-377 (2015).
106. Roberts PJ, Stinchcombe TE, Der CJ, Socinski MA. Personalized medicine in non-small-cell lung cancer: is KRAS a useful marker in selecting patients for epidermal growth factor receptor-Targeted therapy J. Clin. Oncol. 28(31), 4769-4777 (2010).
107. Rosenberg SA, Restifo NP. Adoptive cell transfer as personalized immunotherapy for human cancer. Science 348(6230), 62-68 (2015).
108. Rubio-Perez C, Tamborero D, Schroeder MP et al. In silico prescription of anticancer drugs to cohorts of 28 tumor types reveals targeting opportunities. Cancer Cell 27(3), 382-396 (2015).
109. Stuckey DW, Shah K. Stem cell-based therapies for cancer treatment: separating hope from hype. Nat. Rev. Cancer 14(10), 683-691 (2014).
110. Sharma P, Allison JP. Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential. Cell 161(2), 205-214 (2015).
111. Fang RH, Zhang L. Combinatorial nanotherapeutics: rewiring, then killing, cancer cells. Sci. Signal. 7(325), pe13 (2014).
112. Goldberg MS. Immunoengineering: how nanotechnology can enhance cancer immunotherapy. Cell 161(2), 201-204 (2015).
113. Chow EK-H, Ho D. Cancer nanomedicine: from drug delivery to imaging. Sci. Transl. Med. 5(216) 216-214, 216rv214 (2013).
114. Bach PB, Mirkin JN, Oliver TK et al. Benefits and harms of CT screening for lung cancer: a systematic review. JAMA 307(22), 2418-2429 (2012).
115. Garbuzenko OB, Mainelis G, Taratula O, Minko T. Inhalation treatment of lung cancer: the influence of composition, size and shape of nanocarriers on their lung accumulation and retention. Cancer Biol. Med. 11(1), 44 (2014).
116. Cheng CJ, Tietjen GT, Saucier-Sawyer JK, Saltzman WM. A holistic approach to targeting disease with polymeric nanoparticles. Nat. Rev. Drug Discov. 4(4), 239-247 (2015).
117. Dawidczyk CM, Kim C, Park JH et al. State-of-The-art in design rules for drug delivery platforms: lessons learned from FDA-approved nanomedicines. J. Control. Release 187 133-144 (2014).
118. Gould SE, Junttila MR, De Sauvage FJ. Translational value of mouse models in oncology drug development. Nat. Med. 21(5), 431-439 (2015).